Harvard Bioscience Reports Mixed 2025 Results, Eyes Translational Science Growth
Event summary
- Harvard Bioscience reported Q4 2025 revenues of $23.7M, down from $24.6M in Q4 2024, with a gross margin of 59.7%.
- Full-year 2025 revenues were $86.6M, down from $94.1M in 2024, with a gross margin of 57.7%.
- Mark Frost, interim CFO, appointed permanently as CFO.
- Company introduces 2026 guidance anticipating revenue growth driven by new products for translational science.
- 2025 net loss was $56.7M, primarily due to a $48.0M goodwill impairment in Q1 2025.
The big picture
Harvard Bioscience is pivoting from a traditional life science tools provider to a focus on translational science, aiming to capitalize on the shift to New Approach Methodologies (NAMs). The company's 2025 results reflect a challenging market environment, but its strategic realignment and cost management efforts are positioned to drive future growth. The appointment of Mark Frost as permanent CFO underscores the company's focus on financial stability and operational efficiency.
What we're watching
- Revenue Growth
- Whether Harvard Bioscience can sustain revenue growth in 2026 through new products for translational science.
- Market Conditions
- The pace at which global market conditions and NIH funding stabilize to support revenue recovery.
- Cost Management
- How effective the company's cost containment actions will be in maintaining gross margins.
Related topics